Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

No one product, Merck CEO Clark says, will account for more than 10 percent of the combined company’s sales, which will be nearly $47 billion based on 2008 figures.

You may also be interested in...



Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform

In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises

Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform

In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises

Merck Financial Targets Remain On Track, Despite Generic Cozaar, Health Care Reform

Key brands contributed strong performance, Schering integration is progressing smoothly without interrupting the business' momentum.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel